Literature DB >> 21156411

Multidisciplinary management in rectal cancer.

Asunción Hervás Morón1, María Luisa García de Paredes, Eduardo Lobo Martínez.   

Abstract

The treatment of rectal cancer has evolved over the last few decades from surgery alone to treatments with trimodal therapy for high-risk patients. The involvement of a multidisciplinary team of radiologists, pathologists, surgeons, radiotherapists and medical oncologists is now fundamental for decision-making and outcomes. The evolution of different diagnostic and therapeutic techniques has optimised the therapeutic rate. Future studies will determine the optimal regimen for inducing complete responses in locally advanced disease and whether the intensification of local treatments could enable the use of more conservative treatments, as for other tumour locations. The study of biomarkers will be essential in this respect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156411     DOI: 10.1007/s12094-010-0602-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  123 in total

1.  Laparoscopic surgery for rectal cancer.

Authors:  Shailesh V Shrikhande; Sachin Marda; Mahesh Goel; Guruprasad Shetty
Journal:  Lancet Oncol       Date:  2010-10       Impact factor: 41.316

2.  Preoperative or postoperative therapy for stage II or III rectal cancer: an updated practice guideline.

Authors:  R K S Wong; S Berry; K Spithoff; M Simunovic; K Chan; O Agboola; B Dingle
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-05       Impact factor: 4.126

3.  Prognostic profile in rectal cancer.

Authors:  L Herrera; M T Brown
Journal:  Dis Colon Rectum       Date:  1994-02       Impact factor: 4.585

4.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

5.  Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.

Authors:  Hak-Mien Quah; Joanne F Chou; Mithat Gonen; Jinru Shia; Deborah Schrag; Leonard B Saltz; Karyn A Goodman; Bruce D Minsky; W Douglas Wong; Martin R Weiser
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

6.  Neoadjuvant therapy and anastomotic leak after tumor-specific mesorectal excision for rectal cancer.

Authors:  Guillaume Martel; Youssuf Al-Suhaibani; Husein Moloo; Fatima Haggar; Martin Friedlich; Joseph Mamazza; Eric C Poulin; Hartley Stern; Robin P Boushey
Journal:  Dis Colon Rectum       Date:  2008-06-04       Impact factor: 4.585

Review 7.  Role of MRI for staging of rectal cancer.

Authors:  Kartik S Jhaveri; Arifa Sadaf
Journal:  Expert Rev Anticancer Ther       Date:  2009-04       Impact factor: 4.512

8.  Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.

Authors:  Laurence Collette; Jean-Francois Bosset; Marcel den Dulk; France Nguyen; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Marianne Piérart; Gilles Calais
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

Review 9.  Early rectal cancer: local excision or radical surgery?

Authors:  Alexandre Jin Bok Audi Chang; Caio Sergio Rizkallah Nahas; Sergio E Alonso Araujo; Sergio C Nahas; Carlos F Sparapan Marques; Desiderio Roberto Kiss; Ivan Cecconello
Journal:  J Surg Educ       Date:  2008 Jan-Feb       Impact factor: 2.891

Review 10.  Locally advanced rectal cancer: what is the evidence for induction chemoradiation?

Authors:  Rob Glynne-Jones; Mark Harrison
Journal:  Oncologist       Date:  2007-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.